Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study

NARecruitingINTERVENTIONAL

Enrollment

280

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

September 1, 2024

Study Completion Date

October 11, 2024

Conditions

Non-muscle-invasive Bladder Cancer

Interventions

DRUG

BCG

Intravsical induction and maintenance BCG injections.

DRUG

Gemcitabine

Intravsical induction and maintenance gemcitabin injections.

Trial Locations (1)

RECRUITING

Mohamed Fawzy Salman, Cairo

All Listed Sponsors

lead

Al-Azhar University

OTHER